Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Mauri

Showing results (231-240 of 335) with videos related to

Pageof 34
Sort By:
American Heart Journal|December 5, 2009
Rationale and design of the Patient Related OuTcomes with Endeavor versus Cypher stenting Trial (PROTECT): randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantationEdoardo Camenzind, William Wijns, Laura Mauri, et al.
Biomedicines|May 27, 2023
GM1 Oligosaccharide Efficacy in Parkinson's Disease: Protection against MPTPMaria Fazzari, Giulia Lunghi, Alexandre Henriques, et al.
JACC. Cardiovascular Interventions|March 26, 2013
The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stentAjay J Kirtane, Martin B Leon, Michael W Ball, et al.
FEBS Open Bio|October 27, 2023
GM1 ganglioside exerts protective effects against glutamate-excitotoxicity via its oligosaccharide in wild-type and amyotrophic lateral sclerosis motor neuronsGiulia Lunghi, Erika Di Biase, Emma Veronica Carsana, et al.
Journal of the American College of Cardiology|July 12, 2014
Percutaneous mitral valve repair for mitral regurgitation in high-risk patients: results of the EVEREST II studyDonald D Glower, Saibal Kar, Alfredo Trento, et al.
JACC. Cardiovascular Interventions|August 20, 2011
Saphenous vein graft interventionMichael S Lee, Seung-Jung Park, David E Kandzari, et al.
European Heart Journal|November 21, 2015
Causes of late mortality with dual antiplatelet therapy after coronary stentsLaura Mauri, Sammy Elmariah, Robert W Yeh, et al.
Journal of the American College of Cardiology|April 8, 2011
Clinical evaluation of the Resolute zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries: the RESOLUTE US clinical trialAlan C Yeung, Martin B Leon, Ash Jain, et al.
JAMA Cardiology|March 16, 2017
Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) StudyEric A Secemsky, Robert W Yeh, Dean J Kereiakes, et al.
Circulation|November 8, 2021
Estimation of DAPT Study Treatment Effects in Contemporary Clinical Practice: Findings From the EXTEND-DAPT StudyNeel M Butala, Kamil F Faridi, Hector Tamez, et al.
Pageof 34

Showing results (231-240 of 335) with videos related to

Sort By:
Pageof 34
American Heart Journal|December 5, 2009
Rationale and design of the Patient Related OuTcomes with Endeavor versus Cypher stenting Trial (PROTECT): randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantationEdoardo Camenzind, William Wijns, Laura Mauri, et al.
Biomedicines|May 27, 2023
GM1 Oligosaccharide Efficacy in Parkinson's Disease: Protection against MPTPMaria Fazzari, Giulia Lunghi, Alexandre Henriques, et al.
JACC. Cardiovascular Interventions|March 26, 2013
The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stentAjay J Kirtane, Martin B Leon, Michael W Ball, et al.
FEBS Open Bio|October 27, 2023
GM1 ganglioside exerts protective effects against glutamate-excitotoxicity via its oligosaccharide in wild-type and amyotrophic lateral sclerosis motor neuronsGiulia Lunghi, Erika Di Biase, Emma Veronica Carsana, et al.
Journal of the American College of Cardiology|July 12, 2014
Percutaneous mitral valve repair for mitral regurgitation in high-risk patients: results of the EVEREST II studyDonald D Glower, Saibal Kar, Alfredo Trento, et al.
JACC. Cardiovascular Interventions|August 20, 2011
Saphenous vein graft interventionMichael S Lee, Seung-Jung Park, David E Kandzari, et al.
European Heart Journal|November 21, 2015
Causes of late mortality with dual antiplatelet therapy after coronary stentsLaura Mauri, Sammy Elmariah, Robert W Yeh, et al.
Journal of the American College of Cardiology|April 8, 2011
Clinical evaluation of the Resolute zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries: the RESOLUTE US clinical trialAlan C Yeung, Martin B Leon, Ash Jain, et al.
JAMA Cardiology|March 16, 2017
Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) StudyEric A Secemsky, Robert W Yeh, Dean J Kereiakes, et al.
Circulation|November 8, 2021
Estimation of DAPT Study Treatment Effects in Contemporary Clinical Practice: Findings From the EXTEND-DAPT StudyNeel M Butala, Kamil F Faridi, Hector Tamez, et al.
Pageof 34